pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

psioxus-therapeutics PRESS RELEASE ARCHIVE

Jan 5, 2023

Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics

Aug 11, 2022

PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer

Apr 7, 2021

PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration

Mar 5, 2020

PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer

Nov 15, 2018

PsiOxus Therapeutics to Collaborate with the Parker Institute for Cancer Immunotherapy on Virus-Based Gene Therapy to Treat Solid Tumors

Aug 17, 2017

PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence

Jun 20, 2017

PsiOxus Therapeutics amplía sus operaciones en Oxford, Reino Unido y Filadelfia, Estados Unidos

Jun 20, 2017

PsiOxus Therapeutics élargit ses activités à Oxford, au Royaume-Uni et à Philadelphie, États-Unis

Jun 20, 2017

PsiOxus Therapeutics erweitert seine Geschäftsaktivitäten in Oxford, GB, und Philadelphia, USA

Jun 14, 2017

PsiOxus Therapeutics Expands Operations in Both Oxford, UK and Philadelphia, USA

Dec 20, 2016

Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncolytic Virus to Address Solid Tumors

Sep 16, 2016

PsiOxus Therapeutics Announce Executive Team Reorganization with Two New C Level Appointments in the US

Jun 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Jun 30, 2016

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Apr 14, 2016

Parker Institute for Cancer Immunotherapy and PsiOxus Therapeutics Announce Intention to Collaborate on Tumor-Specific Immuno-Gene Therapy

Mar 10, 2016

PsiOxus Therapeutics Initiates Combination of Paclitaxel with Oncolytic Virus Enadenotucirev in Ovarian Cancer Study

Jan 7, 2016

PsiOxus Therapeutics Appoints Dr Paolo Paoletti as Chairman of the Board

Dec 16, 2015

PsiOxus Therapeutics Initiates Combination Study of Merck’s Keytruda with Oncolytic Virus Enadenotucirev

May 19, 2015

PsiOxus Therapeutics Raises a £25M Series C Investment to Progress Oncolytic Virus Plus Checkpoint Inhibitor Combination Study in Metastatic Colorectal Cancer

Apr 16, 2015

PsiOxus Therapeutics to Present Promising New Data on Novel Oncolytic Immunoncology Platform at AACR 2015

Apr 16, 2015

PsiOxus Therapeutics Expands Clinical Studies for Immuno-Oncolytic Treatment Following Positive Response to Intravenous Delivery

Jun 17, 2014

PsiOxus Therapeutics Initiates ‘OCTAVE’ Ovarian Cancer Study for Oncolytic Vaccine Enadenotucirev

Jun 3, 2014

PsiOxus Therapeutics Announces Positive Study Results of Oncolytic Vaccine Enadenotucirev at 2014 ASCO Annual Meeting

May 13, 2014

PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients

Mar 20, 2013

PsiOxus Therapeutics Comments on Phase III Results from Amgen’s Oncolytic Vaccine

Mar 4, 2013

PsiOxus Therapeutics Completes Patient Enrollment for Phase II Wasting Disease Therapeutic MT-102

Jan 17, 2013

CORRECTING and REPLACING DTRA Awards US$3.3M Contract to PsiOxus Therapeutics to Develop Biodefence Vaccine Adjuvants

Nov 5, 2012

UK Government Awards £1.7M Grant to PsiOxus Therapeutics for Second Phase I/II Clinical Trial of Cancer Vaccine

Jul 9, 2012

PsiOxus Therapeutics Secures £22 Million ($34 Million) in Series B Financing to Drive Clinical Development for Oncolytic Vaccine

Apr 24, 2012

PsiOxus Therapeutics Moves into New Facilities on Milton Park to Accommodate Expansion

Mar 17, 2011

PsiOxus Therapeutics Initiates Phase II Clinical Study of Wasting Disease Therapeutic MT-102

Google Analytics Alternative